AVXS-201, Gene Therapy for Rett, Again Moving Toward Clinical Trial, AveXis Says
Most animal studies needed to support plans to move AVXS-201 — AveXis’ investigational gene therapy for Rett syndrome — into clinical testing in patients are complete, the company reports. AveXis hopes to soon start meeting with the U.S. Food and Drug Administration (FDA) in advance of filing…